))
Behind the Science: CEO of ScanCell, Lindy Durrant on the Company's Breakthrough Antibody Evaluation
Manage episode 438041099 series 3502513
Innhold levert av Karl West. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Karl West eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
In this episode of the All Points West podcast, we sit down with Lindy Durrant, the founder and CEO of AIM-listed ScanCell. Since co-founding ScanCell in 1997, Lindy has been at the forefront of developing groundbreaking immunotherapies for cancer and infectious diseases. With over 25 years of experience in translational research, she has played a pivotal role in bringing monoclonal antibodies and cancer vaccines from the lab to clinical trials. We discuss the rapidly growing immuno-oncology market, the potential of ScanCell's GlyMab platform, and what the future holds for cancer treatment.
25 episoder
Del
